Biopharmaceutical firm Hutchison China MediTech (Chi-Med) has begun a Phase II clinical trial of savolitinib for the treatment of locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China.

Savolitinib is developed as a selective oral inhibitor of mesenchymal epithelial transition factor (c-Met) receptor of an enzyme tyrosine kinase, which was reported to have abnormal functionality in several types of solid tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multi-centre, single-arm, open-label Phase II trial will evaluate the efficacy and safety of savolitinib as a monotherapy in patients harbouring Met gene alterations.

The trial's primary endpoint is objective response rate (ORR), while secondary endpoints include progression free survival (PFS), disease control rate (DCR), duration of response (DoR), overall survival (OS) and safety.

"The multi-centre, single-arm, open-label Phase II trial will evaluate the efficacy and safety of savolitinib as a monotherapy in patients harbouring Met gene alterations."

The drug was reported to have shown encouraging results of clinical efficacy in Phase I trial. It was found to decrease the tumour size in patients with c-Met gene amplification in papillary renal cell carcinoma, non-small-cell lung cancer, colorectal cancer and gastric cancer.

See Also:

The firm is currently evaluating savolitinib in collaboration with AstraZeneca, in several parallel proof-of-concept studies as a monotherapy and in combination with other targeted therapies, immunotherapies and chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chi-Med has recently initiated a Phase I clinical trial of small molecule inhibitor HMPL-453 in Australia, to treat advanced or metastatic solid malignancies.

The open-label, dose-escalation Phase I trial will assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of HMPL-453.